In 2025, Russia aims to initiate the production of three groundbreaking drugs designed to treat rare hereditary diseases. These innovative therapies are the result of research conducted by scientists at Sirius University, under a project backed by the Russian Science Foundation. Roman Ivanov, the director of the University’s Scientific Center for Translational Medicine, delivered this information.
He did not disclose information about the drugs in question. Planned discussions may include drugs like ataluren for Duchenne muscular dystrophy, selexipag for pulmonary hypertension, and risdiplam for spinal muscular atrophy. As reported earlier this year, the technology for acquiring the first two is already in place, while the third is currently in development.
